Papillary thyroid carcinoma with primary hyperparathyroidism: a report of two cases and a brief literature review: Primer Hiperparatiroidizme Eslik Eden Papiller Tiroid Karsinomu Vakasi: 2 Vaka ve Literaturun Kisa Derlemesi.
Coexistence of medullary thyroid carcinoma and primary hyperparathyroidism (PHPT) is well described, however, the association of non-medullary thyroid cancer and PHPT is less recognized. Herein, we report two patients with PHPT and papillary thyroid carcinoma (PTC). Although no definitive data showing increased prevalence of non-medullary thyroid cancer in patients with parathyroid adenomas, possible coexistence of these two conditions should be borne in mind in preoperative evaluation. Turk Jem 2013; 17: 12-4 Key words: Primary hyperparathyroidism, thyroid carcinoma
Meduller tiroit kanseri ve primer hiperparatiroidi birlikteligi oldukca iyi bilinmesine ragmen, meduller disi tiroit kanserleriyle birlikte hiperparatiroidizmin gorulmrsi daha az karsilasilan ve taninan bir durumdur. Biz burada primer hiperparatiroidili, ve papiller tiroit kanserli iki olgumuzu sunacagiz. Paratiroid adenomlanna sahip hastalarda meduller disi tiroit kanseri riskinin arttigini gosteren bir bilgi olmasa da, bu iki hastaligin bir arada bulunabilecegi akilda tutulmalidir. Turk Jem 2013; 17: 12-4
Anahtar kelimeler: Primer hiperparatiroidism, tiroid kanseri
Primary hyperparathyroidism (pHPT) is a common disease. The prevalence rate is about 1 to 4 per 1000, with a female:male ratio of 3:1 (1). By far the most common lesion found in patients with pHPT is solitary parathyroid adenoma occurring in 75%-85% of cases (2). The treatment of choice for pHPT is surgical removal of the adenoma. Papillary thyroid carcinoma IPTC) is the most common type of malignant thyroid tumor, constituting more than 70% of thyroid malignancies (3). There has been an increasing incidence of PTC worldwide over the past few decades (4). Fine needle aspiration biopsy (FNAB) is currently the most common method of examining solitary thyroid nodules. Coexistence of pHPT and PTC has been previously described in case reports and some surgical series. PTC has been reported in 2.1-4.2% of patients subjected to surgery for pHPT in large series (5-10). Herein, we describe two cases of patients with pHPT and PTC
A 55-year-old Caucasian woman was referred to our clinic following determination of profound anemia Hb: 6.4 g/dL) and hypercalcemia (Serum Ca: 11.4 mg/dLI in the internal medicine clinic where she originally presented with lethargy and fatigue. The patient had hypertension and diet-regulated diabetes. She had no history of exposure to radiation. She had a history of nephrolilhiasis 3 years ago. Parathormone (PTH) was 256 pg/ml, urinary calcium--960 mg/day and phosphorus--2.6 mg/dL, at which pHPT was diagnosed. Thyroid function tests and creatinine levels were totally normal. Bilateral millimetric stones were identified by renal ultrasonography (USG). Neck USG revealed multinodular goiter. There were six nodules, the largest size 20x12 mm in diameter with microcalcification. There was a hypoechoic solid lesion measuring 14 x 9 mm in size compatible with a parathyroid adenoma on the left side. FNAB was performed for the nodule with microcalcification. FNAB was positive for PTC. No pathology apart from widespread diverticular lesions was determined by colonoscopy performed for iron deficiency anemia. The anemia was treated with erythrocyte suspension and iron replacement. Total thyroidectomy, central lymph node dissection and parathyroidectomy were performed. In the disease pathology, parathyroid adenoma 12 cm, on the left), multicentric classic variant, papillary carcinoma exhibiting invasion of the capsule outside of the thyroid (in two foci, 2.5 and 1.5 cm, in the left lobe and 1 cm in the pyramidal lobe) and two lymph nodes were identified. On day 7 postoperatively, level of serum Ca fell to 6.6 mg/dL. and PTH to 7.1 pg/mL. The patient was started on calcium and calcitriol replacement. At examinations after 6 weeks postoperatively, no neck pathology was detected by USG and level of serum Ca was measured 8.2 mg/dL under replacement therapy. The patient was administered radioactive iodine treatment with a dose of 100 mCi. Full body scintigraphy that was performed following the treatment revealed no involvement outside the thyroid bed. The patient was started on L-thyroxin therapy at 150 [micro]g/day and placed under observation.
A 60-year-old Caucasian man was referred to our clinic following identification of hypercalcemia (serum Ca: 15.2 mg/dL) in the internal medicine clinic to which he had originally presented with back and lower back pain.The patient had no history of exposure to radiation. Laboratory findings confirmed the diagnosis of pHPT: serum Ca: 15.2 mg/dL, PTH: 1900 pg/mL, urinary calcium: 720 mg/day, serum creatinine: 2.1 mg/dL and alkaline phosphatase: 2142 U/L. Thyroid function tests were normal. Neck USG revealed multinodular goiter. One of the 5 nodules, 23 x 19 mm in size, was hypoechoic and had a satellite nodule and calcification. There was a hypoechoic, solid lesion measuring 18 x 17 mm compatible with a parathyroid adenoma on the right side. FNAB of the nodule was suspicious for PTC. Dual-phase 99 mTc-sestamibi parathyroid scintigraphy was performed (Figure 1). Normal focal activity was observed in the thyroid gland and increased focal activity involvement in the inferior part of the thyroid lobe at images taken at 15 min. Involvement of the thyroid gland disappeared at images taken at 120 min and 4 hour, while increased activity involvement in the inferior part of the right thyroid persisted in a manner compatible with parathyroid adenoma. Isotonic saline at a rate of 4 L/day and 120 mg/day of furosemide were infused repeatedly to improve hypercalcemia during the preoperative period of hospitalization. Then, total thyroidectomy, central lymph node dissection and parathyroideclomy were performed. The pathology report confirmed parathyroid adenoma 13.5 cm) and classic variant PTC 12 cm). Postoperative serum Ca fell to 8.2 mg/dL and PTH to 10 pg/mL. Calcium and calcitriol replacement was started. At examinations 6 weeks after surgery, no neck pathology was detected by USG and level of serum Ca was measured at 8.3 mg/dL under replacement therapy. The patient was given 100 mCi radioactive iodine treatment. At full body scintigraphy 1 week later, there was no involvement outside the thyroid bed. The patient was started on L-thyroxine therapy at 150 [micro]g/day and placed under observation.
Multinodular goiter was incidentally determined while investigating parathyroid adenoma in both cases. PTC was determined in one case following FNAB and in the other as a suspicious biopsy finding. We determined parathyroid adenoma as a result of surgery in both cases. We determined classic type papillary carcinoma, solitary in one case and multicentric in the other.
Although the incidence of PTC associated with pHPT in small surgical series is around 9%-17.8% (11-13), in large series the level has been reported to be 2%-4.2% (5-10). The majority of PTCs in the great majority of these series were microcarcinoma (5), (6), (11). In the great majority of cases, the diagnosis was made through postoperative pathological examination. Additionally, the number of multicentric tumors metastasizing to the lymph nodes was relatively small (5), (6), (11). However, papillary carcinomas without microcarcinoma were more frequent in small series such as those of Kosem et al. (13) and Ogawa et al. (12). The cause of the association between thyroid disease and primary pHPT remains unclear. Although an association between osteosarcoma and pHPT has been shown in animal studies (14), no direct relationship was established between pHPT and cancer in human studies involving 1600 patients given human recombinant PTH (15-17). Some authors suggest a coincidence, however, most maintain that increased endogenous calcium, growth factors, epithelial growth factors, and goitrogenic factors may play a role 18,181. Head and neck radiotherapy, especially during childhood and adolescence, is another risk factor in the pathogenesis of HPTH and thyroid carcinoma (19), (20). However, neither of our patients had any history of radiotherapy. The incidence of thyroid microcarcinoma in large autopsy series (5.3%-6.2%) (21), (22) is similar to the PTC incidence cited in the large surgical series above (5-10). This also suggests that the occurrence of these two diseases together in single individuals is a matter of coincidence.
The reason for detecting the coincidence of thyroid papillary carcinoma and pHPT may be the use of common imaging techniques, such as USG of the neck, in the diagnosis of both diseases. In addition, when surgery to the same region is needed for pathologies of parathyroid, it can be performed in the same session. In such cases, greater attention will be paid to the thyroid. The diagnosis and timely treatment of associated thyroid abnormalities is desirable, because a delay in surgery may result in increased morbidity associated with a second neck exploration. It is, therefore, advisable to evaluate the thyroid gland prior to parathyroid gland operations.
Iakovou et al. (23) reported that a nodule containing papillary carcinoma still exhibited radioactivity in images 3 h later at dual phase 99mTc-sestamibi parathyroid scintigraphy. They suggested that dual phase 99mTc-sestamibi parathyroid scintigraphy might be useful in detecting thyroid malignancy preoperatively. Parathyroid scintigraphy was performed in our second case. While a sestamibi scan can be positive in different benign and malign thyroid tumors (24), we observed no occlusion in the thyroid in images taken at the second and fourth hours.
In conclusion, although synchronous parathyroid and thyroid carcinomas are rare, 1hey can and do coexist. Parathyroid adenomas and multinodular goiter were identified by preoperative USG of the neck in both of our patients. Preoperative FNAB of predominant thyroid nodules was useful in both cases, enabling surgery to be performed more aggressively and preventing a second operation that might increase morbidity and mortality. Although no definitive data showing that non medullary thyroid carcinoma incidence increases in patients with parathyroid adenomas, possible coexistence of both conditions should be borne in mind in preoperative evaluation.
Written informed consent was obtained from the patients for publication of these case reports.
(1.) Heath DA. Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management. Endocrinol Metab Clin North Am 1989;18:631-46.
(2.) Fraser ED. Hyperparathyroidism. Lancet 2009;374:145-58.
(3.) Khan A, Nose V. Differential Diagnosis and Molecular Advances. In: Lloyd RV, ed. Endocrine Pathology (2 th ed). New York; Springer; 2010:181-236.
(4.) Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol 2011;5:51-6.
(5.) Bentrem DJ, Angelos P. Talamonti MS, Nayar R. Is preoperative investigation of the thyroid justified in patients undergoing parathyroidectomy for hyperparathyroidism? Thyroid 2002;12:1109-12.
(6.) Burmeister LA, Sandberg M, Carty SE, Watson CG. Thyroid carcinoma found at parathyroidectomy: association with primary, secondary, and tertiary hyperparathyroidism. Cancer 1997;79:1611-6.
(7.) Linos DA, van Heerden JA, Edis AJ. Primary hyperparathyroidism and nonmedullary thyroid cancer. Am J Surg 1982;143:301-3.
(8.) Krause UC, Friedrich JH, Olbricht T, Metz K. Association of primary hyperparathyroidism and nonmedullary thyroid cancer. Eur J Surg 1996;162:685-9.
(9.) Cinamon U, Turcotte RE. Primary hyperparathyroidism and malignancy: "studies by nature". Bone 2006;39:420-3.
(10.) Attie JN, Vardhan R. Association of hyperparathyroidism with nonmedullary thyroid carcinoma: review of 31 cases. Head Neck 1993;15:20-3.
(11.) Gul K, Ozdemir D, Korukluoglu B, et al. Preoperative and postoperative evaluation of thyroid disease in patients undergoing surgical treatment of primary hyperparathyroidism. Endocr Pract 2010;16:7-13.
(12.) Ogawa T, Kammori M, Tsuji E, et al. Preoperative evaluation of thyroid pathology in patients with primary hyperparathyroidism. Thyroid 2007;17:59-62.
(13.) Kosem M, Algun E, Kotan C, Harman M, Ozturk M. Coexistent thyroid pathologies and high rate of papillary cancer in patients with primary hyperparathyroidism: controversies about minimal invasive parathyroid surgery. Ada Chir Belg 2004;104:568-71.
(14.) Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone 11-341 for 2 years and relevance to human safety. lexical Pathol 2002;30:312-21.
(15.) Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
(16.) Finkelstein JS. Hayes A. Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26.
(17.) Orwoll ES, Scheele WH, Paul 5, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosiss. J Bone Miner Res 2003;18:9-17.
(18.) Fedorak IJ, Salti G, Fulton N, et al Increased incidence of thyroid cancer in patients with primary hyperparathyroidism: a continuing dilemma. Am Surg 1994;60:427-31.
(19.) Stephen AE, Chen KT, Milas M, Siperstein AE. The coming of age of radiation-induced hyperparathyroidism: evolving patterns of thyroid and parathyroid disease after head and neck irradiation. Surgery 2004;136:1143-53.
(20.) De Jong SA, Demeter JG, Jarosz H, Lawrence AM, Paloyan E. Thyroid carcinoma and hyperparathyroidism after radiation therapy for adolescent acne vulgaris. Surgery 1991;110:691-5,
(21.) Lang W, Borrusch H, Bauer L, Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol 1988;90:72-6.
(22.) Martinez-Tello FJ, Martinez-Cabrujo R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer 1993;71:4022-9.
(23.) Iakovou IP, Konstantinidis IE, Chrisoulidou AI, Doumas AS. Synchronous parathyroid adenoma and thyroid papillary carcinoma: a case report. Cases J 2009;30:9121.
(24.) Foldes I, Levay A, Stotz G. Comparative scanning of thyroid nodules with technetium-99m pertechnetate and technetium-99m methoxyisobutylisonitrile. Eur J Nucl Med 1993;20:330-3.
Mehmet Asik, man Anaforoglu *, Mustafa Kose *, Savas Karyagar **, Beyhan Mollamehmetoglu ***, Ekrem Algun *
Canakkale Onsekiz March University Faculty of Medicine, Department of Endocrinology and Metabolism, canakkale, Turkey
* Trabzon Numune Education and Research Hospital, Department of Endocrinology and Metabolism, Trabzon, Turkey
** Trabzon Numune Education and Research Hospital, Department of Nuclear Medicine, Trabzon, Turkey
*** Trabzon Numune Education and Research Hospital, Department of Pathology, Trabzon, Turkey
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Case Report Olgu Sunumu|
|Author:||Asik, Mehmet; Anaforoglu, Inan; Kose, Mustafa; Karyagar, Savas; Mollamehmetoglu, Beyhan; Algun, Ekre|
|Publication:||Turkish Journal of Endocrinology and Metabolism|
|Article Type:||Case study|
|Date:||Mar 1, 2013|
|Previous Article:||Cancer and hypercalcemia; a review of the diagnosis and treatment through an unusual case: Kanser ve Hiperkalsemi; Nadir Gorulen bir Vaka Araciligi...|
|Next Article:||Addison's disease patient presenting with cushing's syndrome findings: Cushing Sendrom Bulgulari ile Prezente olan Addison Hastasi.|